Health technology assessment in Australia: challenges ahead

Terri J Jackson
Med J Aust 2007; 187 (5): . || doi: 10.5694/j.1326-5377.2007.tb01238.x
Published online: 3 September 2007

Australia is well placed to again lead the world in health technology assessment

Australia led the world in 1993 when it introduced the so-called “fourth hurdle” of economic evaluation into the approvals process for drugs (in addition to the usual regulatory “hurdles” of quality, safety, and efficacy).1 We are among the dozen or so developed countries that had invested in health technology assessment (HTA) since the early 1980s, but it was the requirement of a favourable economic evaluation that attracted international attention to HTA in Australia.2 While economic evaluation had always been considered a component of HTA, a policy requiring evidence of cost-effectiveness was groundbreaking.3

  • Terri J Jackson

  • Australian Centre for Economic Research on Health, University of Queensland, Brisbane, QLD.



I am grateful to Judith Healy, Director of RegHealth Program, Regulatory Institutions Network (RegNet), Research School of Social Sciences, Australian National University, for comments and suggestions on a draft of this article.

Competing interests:

Terri Jackson has served as a member of the Medical Services Advisory Committee since 1998.


remove_circle_outline Delete Author
add_circle_outline Add Author

Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.